These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8239608)

  • 41. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Kentepozidis N; Antonopoulou A; Plachouras D; Tsaganos T; Giamarellou H
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):113-7. PubMed ID: 15698716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellou H; Petrikkos G
    Antimicrob Agents Chemother; 1987 Jun; 31(6):959-61. PubMed ID: 3113330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.
    Fernández-Cuenca F; Martínez-Martínez L; Pascual A; Perea EJ
    Chemotherapy; 2003 May; 49(1-2):24-6. PubMed ID: 12714805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD; Wolter DJ
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.
    Craig WA; Redington J; Ebert SC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():29-40. PubMed ID: 1830302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin.
    Staneva M; Markova B; Atanasova I; Terziivanov D
    Antimicrob Agents Chemother; 1994 May; 38(5):981-5. PubMed ID: 8067780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.
    Mimoz O; Jacolot A; Leotard S; Hidri N; Samii K; Nordmann P; Petitjean O
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3304-8. PubMed ID: 9835534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
    Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
    Hanberger H
    Scand J Infect Dis Suppl; 1992; 81():1-52. PubMed ID: 1322561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa.
    Odenholt I; Isaksson B; Nilsson L; Cars O
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):136-41. PubMed ID: 2498095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.